Great Lakes Advisors LLC Invests $2.82 Million in Halozyme Therapeutics, Inc. $HALO

Great Lakes Advisors LLC bought a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 36,039 shares of the biopharmaceutical company’s stock, valued at approximately $2,821,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HALO. Norges Bank purchased a new stake in Halozyme Therapeutics in the fourth quarter worth $128,201,000. William Blair Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $124,031,000. Voloridge Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $77,587,000. Qube Research & Technologies Ltd bought a new position in Halozyme Therapeutics in the second quarter worth about $51,295,000. Finally, Assenagon Asset Management S.A. raised its stake in Halozyme Therapeutics by 4,578.9% in the second quarter. Assenagon Asset Management S.A. now owns 997,643 shares of the biopharmaceutical company’s stock worth $78,086,000 after buying an additional 976,321 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on HALO shares. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. UBS Group reissued a “buy” rating and set a $90.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, August 14th. TD Cowen upped their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Finally, Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

Halozyme Therapeutics Trading Down 1.4%

Halozyme Therapeutics stock opened at $106.12 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $61.22 and a 12 month high of $107.96. The company has a market capitalization of $12.04 billion, a price-to-earnings ratio of 31.68, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. The business’s fifty day simple moving average is $82.42 and its two-hundred day simple moving average is $73.50. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same quarter in the previous year, the firm earned $1.54 EPS. Halozyme Therapeutics’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $104.18, for a total transaction of $2,083,600.00. Following the completion of the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at $79,987,320.40. This trade represents a 2.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the transaction, the director owned 14,462 shares of the company’s stock, valued at approximately $1,084,650. The trade was a 33.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 64,103 shares of company stock valued at $5,226,496. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.